Introduction
Cerebral amyloid angiopathy (CAA) is an important cause of intracerebral hemorrhage (ICH) in the elderly. This devastating event has a high mortality and frequently leaves survivors in a state of dependency. ICH in this disease is caused by vessel fragility and breakdown due to deposition of β-amyloid (Aβ) within the walls of small cortical and leptomeningeal arteries.
The incidence of CAA-related ICH may be increasing. The aging of the population is expected to lead to an increasing incidence because the strongest risk factor for CAA is age [1] . Also, CAA has been determined to be a risk factor for anticoagulant-related ICH [2] . Therefore, if indications for anticoagulation or thrombolysis increase in the elderly (eg, for treatment of coronary artery disease), an increase in CAA-related ICH may well result. Finally, improved treatment of hypertension is expected to lead to a decrease in the overall incidence of ICH, but may lead to an increased proportion of ICH due to CAA, as the pathophysiology of CAA-related ICH is not largely dependent on hypertension.
As is the case with most neurodegenerative disorders, definitive diagnosis of CAA requires autopsy. However, there is a need to make an ante-mortem diagnosis of CAA in order to determine prognosis and gauge the safety of the use of anticoagulants or antiplatelet drugs. Also, patients must be given a presumptive diagnosis while alive in order to study the disease and to perform clinical trials if, as expected, compounds are developed that modify Αβ production, aggregation, or clearance. In order to meet these needs, a set of criteria for the diagnosis of CAA were developed in 1995 and 1996 by Drs. Steven Greenberg, Daniel Kanter, Carlos Kase, and Michael Pessin and are referred to as the Boston Criteria [3, 4] . The aim of this article is to review the validity of the Boston Criteria and to describe the clinical and laboratory features of CAArelated ICH that can be used for presumptive diagnosis in living patients.
Pathogenesis of Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy is caused by the deposition of Aβ within the arterial media and adventitia, which if severe enough will lead to vessel fragility, rupture, and formation of macroscopic or microscopic hematomas [5] . Pathologically, intensely staining deposits of eosinophilic and congophilic Aβ are seen, sometimes with the presence of distinctive double lumen vessels. Fibrinoid necrosis and microaneurysms are present in severely affected vessels [6] . Affected vessels are medium-and small-sized arteries and arterioles in the cortical parenchyma and leptomeninges [1]; there is little or no deposition in similar-sized vessels within the cerebral white matter. CAA is not associated with any of the systemic amyloidoses.
β-Amyloid is the same 39-43 amino acid peptide that is deposited within the brain parenchyma in Alzheimer's disease. CAA and Alzheimer's disease often, but not invariably, co-exist. CAA patients have an increased prevalence of parenchymal Aβ plaques [5] , and of patients with CAA-related ICH, 25% to 40% have a pre-existing history of dementia [6] . Conversely, patients with Alzheimer's Cerebral amyloid angiopathy is a disorder in which deposition of amyloid within the arterial media and adventitia leads to intracerebral hemorrhage. Diagnosis during life has been hampered by the requirement for post-mortem examination for definitive diagnosis. The Boston Criteria for the diagnosis of cerebral amyloid angiopathy-related hemorrhage were developed in 1995 and 1996 in order to meet the need for a standardized set of diagnostic criteria that can be applied to living patients. Using a combination of clinical, radiologic, and pathologic data, these criteria reliably differentiate lobar intracerebral hemorrhage into categories of possible, probable, or definite based on the likelihood of underlying cerebral amyloid angiopathy. These criteria will be crucial for disease classification for future clinical studies.
disease also have an increased prevalence of CAA, with 25% of patients in a consecutive autopsy series showing moderate or severe CAA [7] . Shared risk factors, such as advanced age and apolipoprotein E genotype, may explain part of the association between CAA and Alzheimer's disease. It is important to note, however, that the presence of dementia in a patient with lobar ICH is neither sensitive nor specific for the presence of CAA and is not a diagnostic criterion for this disease.
β-Amyloid is produced by the degradation of the amyloid precursor protein (APP). Although familial CAA due to mutations in the APP gene has been described [8, 9] , the vast majority of cases are sporadic, and age appears to be the strongest risk factor [1] . Although the incidence of CAA-related ICH is relatively low, the presence of CAA on general autopsy series is much higher and is highly dependent on age [1, 10, 11] . For example, in one study 43% of patients over 70 years of age had evidence of at least some CAA, with half of them showing moderate to severe CAA [1] . In the same study, the prevalence was 57% in patients over 90 years of age. Therefore, ICH occurs in only a minority of patients with pathologic evidence of CAA. In the absence of ICH, there is still a possibility that vascular amyloid deposition could lead to symptoms by causing brain ischemia and cognitive impairment. Therefore, it is not clear what level of CAA deposition can be considered truly asymptomatic.
Apolipoprotein E genotype is related to the occurrence of CAA-related ICH. Apolipoprotein E exists in three major allelic forms, designated ε2, ε3, and ε4. The ε2 allele is over-represented in patients with CAA-related ICH, where it appears to act by increasing the fragility of amyloidladen vessels [12] [13] [14] [15] . The ε4 allele is also associated with CAA and CAA-related ICH, independently of its association with Alzheimer's disease [3, 16] . The presence of the ε4 allele is associated with more severe amyloid burden per vessel in CAA, but not an increase in the number of affected vessels [17] . Both the ε2 and ε4 alleles have been linked with an increased risk of recurrent lobar ICH [18••] .
Clinical Features of Cerebral Amyloid Angiopathy
The diagnosis of CAA is most often considered when an elderly patient presents with ICH in the cortical or corticosubcortical regions of the brain, referred to also as lobar ICH. The location of these hemorrhages is distinct from ICH in the deep brain regions (putamen, thalamus, caudate nucleus, and brain stem) that are commonly associated with hypertension. CAA is among the most common causes of lobar hemorrhage in the elderly [19] , whereas other causes such as vascular malformations predominate in younger patients.
Cerebral amyloid angiopathy should be considered in any patient over the age of 55 years who presents with lobar ICH. The presence of hypertension should not deter the physician from diagnosing CAA-related ICH, as both hypertension and CAA increase with age and often co-exist. A history of multiple ICH as determined by history or radiologic imaging favors the diagnosis of CAA-related ICH, as the rate of recurrent ICH is high in this disease. There is a slight predilection for frontal and parietal brain regions [5] .
Cerebral amyloid angiopathy-related ICH may occasionally occur in non-lobar brain regions. The cerebellum is known to contain a variable amount of vascular amyloid and can rarely be the site of hemorrhage [20, 21] . Because lobar hemorrhages occur in cortical regions near the pial surface, dissection of the hematoma into the subarachnoid space is common. Rarely, subarachnoid hemorrhage without radiographically apparent intraparenchymal blood may be caused by CAA [22] .
Overall mortality is in the range of 10% to 40% [18••,23-27] . Variables of prognostic significance include age, level of consciousness, and hematoma volume [26, 28, 29] . A substantial proportion of survivors is left with chronic disability. A major cause of further morbidity is recurrent hemorrhage, which happens much more commonly than in hypertensive ICH. The annual recurrence rate has been estimated to be 4.4% to 14.1% [18••,30] [32] [33] [34] . Dementia frequently accompanies CAA, often as the result of co-existent Alzheimer's disease, but also sometimes due to CAA itself. In these cases, a severe leukoencephalopathy may arise from white matter ischemia [35] [36] [37] , possibly caused by vessel narrowing or loss of autoregulation due to amyloid deposition. Rarely, the presence of Aβ may induce an inflammatory vasculitic reaction [38] that can be responsive to immunomodulatory treatment. Presentation as a brain mass ("amyloidoma") has been described [39, 40] .
Diagnosis of Cerebral Amyloid Angiopathy by Pathology
Definitive confirmation of CAA is obtained when microscopic examination of brain or leptomeningeal tissue reveals hyaline eosinophilic material in the arterial media or adventitia consistent with Aβ. Characteristic apple-green birefringence is seen when the slide is stained with Congo red and viewed under polarization microscopy ( Fig. 1) . Immunohistochemical staining for Aβ peptide will also confirm the presence of Aβ in the vessel walls.
Whole-brain examination at autopsy is the best means of determining the diagnosis of CAA, but evaluation of
